Premium
Effect of plant sterol esters on cardiovascular risk factors in hypercholesterolemic adults
Author(s) -
Sauder Katherine A,
Psota Tricia L,
Kris-Etherton Penny M,
Bagshaw Deborah,
Alaupovic Peter,
West Sheila G
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.1015.6
Subject(s) - sterol , cholesterol , placebo , crossover study , blood pressure , food science , blood lipids , medicine , apolipoprotein b , endocrinology , zoology , chemistry , biology , alternative medicine , pathology
Daily consumption of plant sterol esters has been shown to decrease total and LDL cholesterol. We examined whether delivery of plant sterol esters in a low‐fat dairy dessert could decrease cardiovascular risk factors. We enrolled 49 hypercholesterolemic adults in a randomized, double‐blind, crossover study with 4‐week control and treatment periods. Participants consumed two 68g portions of the dessert daily, providing 2 g/d free plant sterols, and were counselled to follow the Therapeutic Lifestyle Changes diet. Lipids, apolipoproteins, cellular adhesion molecules (CAM), inflammatory markers, blood pressure, and cardiovascular reactivity to stress were assessed at baseline and after each treatment period. Total and LDL cholesterol decreased more after consumption of the plant sterol dessert compared to placebo (−6.0% vs −2.4% and −8.3% vs −2.7%, respectively, p<0.0001). Apolipoprotein A‐I increased after the plant sterol dessert (p<0.05). No significant changes were observed between treatments for HDL, triglycerides, CAM, and inflammatory markers. Blood pressure and total peripheral resistance during stress were lower following the placebo dessert compared to the plant sterol dessert (p<0.05). These results demonstrate that delivering 2 g/d of free plant sterols through a low‐fat dairy dessert for four weeks is clinically effective in reducing total and LDL cholesterol. Funding: Unilever